BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 46,200 shares, an increase of 59.3% from the September 30th total of 29,000 shares. Based on an average trading volume of 100,500 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of BrainsWay in a research note on Monday, October 21st. Northland Securities lifted their target price on BrainsWay from $11.00 to $12.50 and gave the company an "outperform" rating in a research note on Thursday, October 3rd.

Institutional Investors Weigh In On BrainsWay

Several large investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after purchasing an additional 1,695 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in BrainsWay in the 4th quarter worth approximately $70,000. Virtu Financial LLC acquired a new stake in BrainsWay in the 1st quarter worth approximately $60,000. Perritt Capital Management Inc acquired a new stake in BrainsWay in the 2nd quarter worth approximately $121,000. Finally, Good Life Advisors LLC lifted its holdings in BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after purchasing an additional 22,080 shares during the last quarter. Institutional investors own 30.11% of the company's stock.

BrainsWay Stock Performance

Shares of NASDAQ BWAY traded down $0.03 during trading hours on Friday, hitting $9.65. The stock had a trading volume of 31,739 shares, compared to its average volume of 95,714. The company has a market capitalization of $160.82 million, a P/E ratio of -107.22 and a beta of 1.26. The firm's 50-day moving average price is $8.58 and its two-hundred day moving average price is $6.98. BrainsWay has a 52 week low of $3.09 and a 52 week high of $10.61.

BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. The business had revenue of $10.01 million during the quarter, compared to analysts' expectations of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same quarter in the previous year, the business posted ($0.05) EPS. As a group, analysts expect that BrainsWay will post 0.06 EPS for the current fiscal year.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.